Article Figures & Data
Figures
- FIGURE 1.
89Zr-DFO-MSTP2109A maximum-intensity projections of selected patients with bone metastases of various extents. Images were acquired at 6 d after injection and are displayed at same gray scale with SUVmax of 10. Patients in upper panel (particularly patients 3 and 9) have extensive metastatic bone disease. Uptake in noninvolved bone is low and not definitely seen in projection images. Physiologic blood-pool activity was prominent soon after injection, and much less blood-pool activity is seen in late images in those with more extensive bony disease. Uptake in liver is partially reflective of blood-pool activity and parenchymal accumulation. Low-level uptake is also noted in kidneys, and variable uptake is noted in bowel (intraluminal), which probably represents route of excretion.
- FIGURE 2.
89Zr-DFO-MSTP2109A images of patient 13 obtained 6 d after injection. Images showed bone uptake in vertebral lesion (middle panel, midline arrow), in addition to uptake in left axillary node (middle panel arrow in left axilla) that was biopsy-proven metastatic disease. Left cervical nodal uptake (left panel, arrow) and retroperitoneal node (right panel, arrow) showed abnormal uptake. Although these were negative on concurrent CT, follow-up 18F-FDG scan showed mild uptake at these sites.
- FIGURE 3.
Number of lesions identified on 89Zr-DFO-MSTP2109A correlated negatively with clearance of radioactivity from blood pool. SUVmean in blood was lower in patients with higher number of lesions when all 19 patients were considered (last scan, 4–8 d) (Pearson r = −0.78, P = 0.0001) or when patients were scanned on most common day, which was 6 d (n = 16) (Pearson r = −0.91, P < 0.0001).
Tables
Bone lesions Soft-tissue lesions* Patient no. 89Zr-DFO-MSTP2109A+ Bone scan+ CT+ CIM+ 89Zr-DFO-MSTP2109A+ CT+ 1 34 31 16 32 1 1 2 71 73 7 73 0 0 3 80 88 74 88 6 2 4 8 54 50 66 0 0 5 3 4 5 8 0 0 6 32 41 17 45 0 0 7 27 30 22 31 0 0 8 40 84 71 85 0 0 9 83 80 31 80 5 1 10 4 2 0 2 2 2 11 17 14 7 14 8 3 12 8 30 10 33 0 0 13 9 22 17 25 4 0 14 5 6 13 14 6 0 15 30 38 37 51 0 0 16 20 11 4 11 0 0 17 1 0 0 0 6 2 18 32 27 14 31 0 0 19 11 15 18 19 0 0 Total 515 650 413 708 38 11 ↵* Nodes, liver, lung, and prostatic bed.
- TABLE 2
Correlation Between SUVmax in Tumor vs. Patient Outcome, PSA, and Immunohistochemistry
Parameter compared with SUVmax Correlation Time from imaging injection to death Pearson r = −0.12, P = 0.62 (n = 19) Time on DSTP3086S ADC treatment Pearson r = −0.59, P = 0.054 (n = 16) Baseline PSA level Pearson r = 0.1, P = 0.67 (n = 19) Maximal PSA change after DSTP3086S ADC treatment vs. baseline Pearson r = −0.496, P = 0.576 (n = 16) Highest immunohistochemistry value (archival or fresh) vs. SUVmax Spearman r = 0.37, P = 0.12 (n = 19) Immunohistochemistry value for fresh tissue vs. SUVmax Spearman r = 0.0976, P = 0.803 (n = 6) Bone lesions Soft-tissue lesions Agent Bone scan+ Bone scan− CT+ CT− CIM+ CIM− CT+ CT− Total 89Zr-DFO-MSTP2109A+ 433 82 253 262* 443 72 9 29 38 89Zr-DFO-MSTP2109A− 217 48 160 105 265 NA 2 NA Total 650 130 413 367 708 72 11 29 ↵* 24 sites identified on 89Zr-DFO-MSTP2109A were not in CT field of view; 18 bone scan sites were not in CT field of view.
CIM = conventional imaging modality.
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Circulating Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in 11C Choline-identified Oligometastatic Castration-Refractory Prostate Cancer Treated with Stereotactic Ablative Radiotherapy
- Cryo-electron microscopy structure and potential enzymatic function of human six-transmembrane epithelial antigen of the prostate 1 (STEAP1)